Systemic Anti-Cancer Therapy Regimen Library New Zealand Formulary

Neuroendocrine Regimens

Adrenocortical carcinoma Regimens

Published Sort regimens by
Adrenocortical carcinoma Advanced - EDP [etoposide, DOXOrubicin and cISplatin] and mitotane Id: 587901000210102 Published date: Version: 1.0.0
587901000210102
1.0.0
04/06/2026

Neuroendocrine carcinoma Regimens

Published Sort regimens by
Neuroendocrine carcinoma Advanced - cARBOplatin and etoposide Id: 265491000210102 Published date: Version: 1.0.0
265491000210102
1.0.0
11/09/2023
Neuroendocrine carcinoma Advanced - cARBOplatin and oral etoposide Id: 265521000210104 Published date: Version: 1.0.0
265521000210104
1.0.0
11/09/2023
Neuroendocrine carcinoma Advanced - CETUximab [Q2W] and encorafenib Id: 506321000210105 Published date: Version: 1.0.0
506321000210105
1.0.0
21/04/2025
Neuroendocrine carcinoma Advanced - mFOLFIRI [irinotecan, foliNIc acid and fluorouracil] [high dose foliNIc acid] Id: 587891000210103 Published date: Version: 1.0.0
587891000210103
1.0.0
04/06/2026
Neuroendocrine carcinoma - cISplatin and etoposide 60/120 chemoradiation Id: 265711000210103 Published date: Version: 2.0.0
265711000210103
2.0.0
08/05/2026
Neuroendocrine carcinoma - cISplatin and etoposide 80/100 chemoradiation Id: 265701000210100 Published date: Version: 2.0.0
265701000210100
2.0.0
08/05/2026
Superseded Regimens Sort regimens by
Neuroendocrine carcinoma Advanced - mFOLFIRI [irinotecan, foliNIc acid and fluorouracil [bolus and infusion]] [high dose foliNIc acid] Id: 265721000210108 Published date: Version: 1.0.2
265721000210108
1.0.2
16/06/2026

Neuroendocrine neoplasm Regimens

Published Sort regimens by
Neuroendocrine neoplasm Advanced - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid] Id: 587881000210100 Published date: Version: 1.0.0
587881000210100
1.0.0
04/06/2026
Neuroendocrine neoplasm Advanced - mFOLFOXIRI [irinotecan, oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid] Id: 506341000210104 Published date: Version: 2.0.0
506341000210104
2.0.0
01/04/2026
Superseded Regimens Sort regimens by
Neuroendocrine neoplasm Advanced - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil [bolus and infusion]] [high dose foliNIc acid] Id: 265731000210105 Published date: Version: 1.0.2
265731000210105
1.0.2
16/06/2026

Neuroendocrine tumour Regimens

Published Sort regimens by
Neuroendocrine tumour Advanced - capecitabine and temozolomide [ONCE daily dosing] Id: 506441000210109 Published date: Version: 1.0.0
506441000210109
1.0.0
08/05/2025
Neuroendocrine tumour Advanced - capecitabine and temozolomide [TWICE daily dosing] Id: 587861000210108 Published date: Version: 1.0.0
587861000210108
1.0.0
04/06/2026
Neuroendocrine tumour Advanced - capecitabine and temozolomide [TWICE daily dosing for use with PRRT] Id: 587871000210102 Published date: Version: 1.0.0
587871000210102
1.0.0
04/06/2026
Neuroendocrine tumour Advanced - everolimus Id: 265511000210109 Published date: Version: 1.0.0
265511000210109
1.0.0
11/09/2023
Neuroendocrine tumour Advanced - lanreotide Id: 506361000210103 Published date: Version: 1.0.0
506361000210103
1.0.0
28/04/2025
Neuroendocrine tumour Advanced - octreotide modified release Id: 506941000210103 Published date: Version: 1.0.0
Components ▾
octreotide modified release 20 mg Q4W Id: 506951000210100 Published date: Version: 0.0.8
octreotide modified release 30 mg Q4W Id: 506961000210102 Published date: Version: 0.0.8
octreotide modified release 10 mg Q4W Id: 506971000210108 Published date: Version: 0.0.3
octreotide modified release 40 mg Q4W Id: 506981000210105 Published date: Version: 0.0.9
octreotide modified release 50 mg Q4W Id: 506991000210107 Published date: Version: 0.0.5
octreotide modified release 60 mg Q4W Id: 507001000210102 Published date: Version: 0.0.8
octreotide modified release 10 mg Q3W Id: 507011000210100 Published date: Version: 0.0.3
octreotide modified release 20 mg Q3W Id: 507021000210105 Published date: Version: 0.0.3
octreotide modified release 30 mg Q3W Id: 507031000210107 Published date: Version: 0.0.3
octreotide modified release 40 mg Q3W Id: 507041000210104 Published date: Version: 0.0.3
octreotide modified release 10 mg Q2W Id: 587831000210104 Published date: Version: 0.0.3
octreotide modified release 20 mg Q2W Id: 587841000210107 Published date: Version: 0.0.3
octreotide modified release 30 mg Q2W Id: 587851000210105 Published date: Version: 0.0.4
506941000210103
1.0.0
04/06/2026
Neuroendocrine tumour Advanced - peptide receptor radionuclide therapy [PRRT] for pheochromocytoma/paraganglioma Id: 587911000210100 Published date: Version: 1.0.0
587911000210100
1.0.0
04/06/2026
Neuroendocrine tumour Advanced - short-acting octreotide Id: 587961000210103 Published date: Version: 1.0.0
Components ▾
Test dose Id: 587971000210109 Published date: Version: 0.0.4
Short-acting octreotide Id: 587981000210106 Published date: Version: 0.0.7
587961000210103
1.0.0
16/06/2026
Neuroendocrine tumour Advanced - streptozocin and fluorouracil Id: 587921000210105 Published date: Version: 1.0.0
587921000210105
1.0.0
16/06/2026
Neuroendocrine tumour PANC Advanced - leNVAtinib Id: 506931000210106 Published date: Version: 1.0.0
506931000210106
1.0.0
04/06/2026
Neuroendocrine tumour PANC Advanced - sUNITinib Id: 265501000210107 Published date: Version: 1.0.0
265501000210107
1.0.0
11/09/2023